Specific considerations on the prescription and therapeutic interchange of statins;Consideraciones específicas en la prescripción e intercambio terapéutico de estatinas

Farmacia Hospitalaria

Volumn 36, Issue 2, 2012, Pages 97-108

  Garcia Sabina A ^a   Gulin Davila J ^a   Sempere Serrano, P ^a   Gonzalez Juanatey C ^a   Martinez Pacheco R ^b  

^a HOSPITAL UNIVERSITARIO LUCUS AUGUSTI   (Spain)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Atorvastatin; Drug interactions; Fluvastatin; Hydroxymethylglutaryl CoA reductase inhibitors; Lovastatin; Pharmacokinetics; Pitavastatin; Pravastatin; Rosuvastatin; Simvastatin; Therapeutic equivalence

Indexed keywords

ATORVASTATIN; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; FLUINDOSTATIN; GLYCOPROTEIN P; ISOENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; DRUG INDICATION; DRUG INDUSTRY; DRUG METABOLISM; HUMAN; LIVER CELL; PRESCRIPTION; SPAIN;

EID: 84858334119     PISSN: 11306343     EISSN: 21718695     Source Type: Journal    
DOI: 10.1016/j.farma.2011.02.010     Document Type: Short Survey

References (109)

1. D. Steinberg The Statins in Preventive Cardiology N Engl J Med 29 2009 541 542
2. A. Endo A historical perspective on the discovery of statins Proc Jpn Acad Ser B Phys Biol Sci 86 2010 484 493
3. M. Schachter Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update Fundam Clin Pharmacol 19 2005 117 125 (Pubitemid 40204354)
4. J.K. Liao Beyond lipid lowering: the role of statins in vascular protection Int J Cardiol 86 2002 5 18 (Pubitemid 35247880)
5. Lou Arnal S, Rodríguez Roca G. Displipemias. Factores de riesgo cardiovacular. Documentos clínicos SEMERGEN. 2005; 23-35 [citado 15 Ene 2011]. Disponible en: http://www.semergen.es/semergen/contentFiles/13693/es/ dislipemias.pdf.
6. Suárez Fernández C. Protocolos de riesgo cardiovascular de la SEMI. 2004; 18-19 [citado 15 Ene 2011]. Disponible en: http://www.fesemi.org/ grupos/riesgo-c/publicaciones/protocolos-riesgo-vascular.pdf.
7. Y. Cui, D.J. Watson, C.J. Girman, D.R. Shapiro, A.M. Gotto, and P. Hiserote Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study) Am J Cardiol 104 2009 829 834
8. M.R. Law, N.J. Wald, and A.R. Rudnicka Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis BMJ 326 2003 1423 1427 (Pubitemid 36776152)
9. H.J. Juridique, B.A. Hutten, C. Gagné, G. Langslet, B.W. McCrindle, and A. Wiegman Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia J Am Coll Cardiol 55 2010 1121 1126
10. P.H. Jones, M.H. Davidson, E.A. Stein, H.E. Bays, J.M. McKenney, and E. Miller Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial) Am J Cardiol 92 2003 152 160 (Pubitemid 36835963)
11. W.V. Brown, H.E. Bays, D.R. Hassman, J. McKenney, R. Chitra, and H. Hutchinson Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial Am Heart J 144 2002 1036 1043 (Pubitemid 36026917)
12. J.E. Edwards, and R.A. Moore Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials BMC Fam Pract 2003 4 18
13. A. e-mecum. García Sabina Ayuda en la toma de decisiones farmacoterapéuticas 2009 Editorial Médica A.W.W.E.
14. M.G. Kendrach, and M. Kelly-Freeman Approximate equivalent rosuvastatin doses for temporary statin interchange programs Ann Pharmacother 38 2004 1286 1292 (Pubitemid 38802177)
15. D. Nakai, R. Nakagomi, Y. Furuta, T. Tokui, T. Abe, and T. Ikeda Human liver-specific organic anion transporter. LST-1, mediates uptake of pravastatin by human hepatocytes J Pharmacol Exp Ther 297 2001 861 867 (Pubitemid 32472480)
16. S. Bellosta, R. Paoletti, and A. Corsini Safety of statins: focus on clinical pharmacokinetics and drug interactions Circulation 109 2004 III50 III57
17. M. Igel, T. Sudhop, and K. von Bergmann Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins) Eur J Clin Pharmacol 57 2001 357 364 (Pubitemid 33787186)
18. J. Brockmoller, J. Kirchheiner, C. Meisel, and I. Roots Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment Pharmacogenomics 1 2000 125 151
19. P.J. Neuvonen, M. Niemi, and J.T. Backman Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance Clin Pharmacol Ther 80 2006 565 581 (Pubitemid 44908269)
20. S. Matsushima, K. Maeda, C. Kondo, M. Hirano, M. Sasaki, and H. Suzuki Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein J Pharmacol Exp Ther 314 2005 1059 1067 (Pubitemid 41205969)
21. A.L. Catapano Pitavastatin - pharmacological profile from early phase studies Atheroscler Suppl 11 2010 3 7
22. Y. Shirasaka, K. Suzuki, M. Shichiri, T. Nakanishi, and I. Tamai Intestinal Absorption of HMG-CoA Reductase Inhibitor Pitavastatin Mediated by Organic Anion Transporting Polypeptide and P-Glycoprotein/Multidrug Resistance 1 Drug Metab Pharmacokinet 26 2011 171 179
23. P.J. Neuvonen, J.T. Backman, and M. Niemi Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin Clin Pharmacokinet 47 2008 463 474 (Pubitemid 351861958)
24. M. Oscarson Pharmacogenetics of drug metabolising enzymes: importance for personalised medicine Clin Chem Lab Med 41 2003 573 580 (Pubitemid 36603276)
25. S.P. Romaine, K.M. Bailey, A.S. Hall, and A.J. Balmforth The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy Pharmacogenomics J 10 2010 1 11
26. R.J. Herman Drug interactions and the statins CMAJ 161 1999 1281 1286
27. S. Bellosta, R. Paoletti, and A. Corsini Safety of statins: focus on clinical pharmacokinetics and drug interactions Circulation 109 2004 Jun 15 III50 III57
28. C. Kyrklund, J.T. Backman, K.T. Kivistö, M. Neuvonen, J. Laitila, and P.J. Neuvonen Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations Clin Pharmacol Ther 68 2000 592 597 (Pubitemid 32059984)
29. M. Ucar, M. Neuvonen, H. Luurila, R. Dahlqvist, P.J. Neuvonen, and T. Mjörndal Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid Eur J Clin Pharmacol 59 2004 879 882 (Pubitemid 38333678)
30. C.W. Holtzman, B.S. Wiggins, and S.A. Spinler Role of P-glycoprotein in statin drug interactions Pharmacotherapy 26 2006 1601 1607 (Pubitemid 44704473)
31. E. Wang, C.N. Casciano, R.P. Clement, and W.W. Johnson HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein Pharm Res 18 2001 800 806 (Pubitemid 32783516)
32. D.W. Schneck, B.K. Birmingham, J.A. Zalikowski, P.D. Mitchell, Y. Wang, and P.D. Martin The effect of gemfibrozil on the pharmacokinetics of rosuvastatin Clin Pharmacol Ther 75 2004 455 463 (Pubitemid 38534566)
33. R. Nakagomi-Hagihara, D. Nakai, T. Tokui, T. Abe, and T. Ikeda Gemfibrozil and its glucuronide inhibit the hepatic uptake of pravastatin mediated by OATP1B1 Xenobiotica 37 2007 474 486 (Pubitemid 46809115)
34. COF Navarra. Cerivastatina: reflexiones sobre su retirada. Boletin Informativo de Farmacovigilancia. Número 22 [citado 15 Ene 2011]. Disponible en: http://www.cfnavarra.es/bif/DEFAULT.HTML.
35. K. Wenke Management of hyperlipidaemia associated with heart transplantation Drugs 64 2004 1053 1068 (Pubitemid 38736894)
36. Ficha técnica de Lymetel® (fluvastatina), texto actualizado Mayo 2007. Lab ANDROMACO, S.A.
37. J. Kahri, M. Valkonen, T. Bäcklund, M. Vuoristo, and K.T. Kivistö Rhabdomyolysis in a patient receiving atorvastatin and fluconazole Eur J Clin Pharmacol 60 2005 905 907 (Pubitemid 40386163)
38. R. Hazin, J.Y. Abuzetun, and M. Suker Rhabdomyolysis induced by simvastatin-fluconazole combination J Natl Med Assoc 100 2008 444 446 (Pubitemid 351556507)
39. T. Kantola, J.T. Backman, and M. Niemi Effect of fluconazole on plasma fluvastatin and pravastatin concentrations Eur J Clin Pharmacol 56 2000 225 229 (Pubitemid 30456682)
40. Ficha técnica de Alcosin® (simvastatina), texto actualizado Abril 2006. Industria Química Farmacéutica VIR, S.A.
41. T.A. Jacobson Comparative interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors Am J Cardiol 94 2004 1140 1146 (Pubitemid 39424216)
42. P.J. Neuvonen, T. Kantola, and K.T. Kivistö Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole Clin Pharmacol Ther 63 1998 332 341 (Pubitemid 28182231)
43. K.T. Kivistö, T. Kantola, and P.J. Neuvonen Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin Br J Clin Pharmacol 46 1998 49 53 (Pubitemid 28308424)
44. T. Kantola, K.T. Kivistö, and P.J. Neuvonen Effect of itraconazole on the pharmacokinetics of atorvastatin Clin Pharmacol Ther 64 1998 58 65 (Pubitemid 28377331)
45. A.L. Mazzu, K.C. Lasseter, E.C. Shamblen, V. Agarwal, J. Lettieri, and P. Sundaresen Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin Clin Pharmacol Ther 68 2000 391 400
46. P.J. Neuvonen, and K.M. Jalava Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid Clin Pharmacol Ther 60 1996 54 61 (Pubitemid 26279221)
47. Información técnica de Pravastatin; texto actualizado Marzo 2008. Mylan Pharmaceuticals Inc (Morgantown, WV -EE.UU.-).
48. Ficha técnica de Zarator® (atorvastatina), texto actualizado Julio 2010. Lab PARKE-DAVIS, S.L. (Grupo Pfizer).
49. Ficha técnica de Lovastatina-Normon®, texto actualizado Mayo 2005. Lab NORMON S.A.
50. T. Niwa, T. Shiraga, and A. Takagi Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes Biol Pharm Bull 28 2005 1805 1808 (Pubitemid 41324160)
51. Información técnica de Noxafil® susp (posaconazol); texto actualizado Septiembre 2010. Schering Corporation.(Kenilworth, NJ-USA).
52. Ficha técnica de VFEND® (voriconazol), texto actualizado 22 Marzo 2006. Lab Pfizer Limited.
53. S. Jeong, P.D. Nguyen, and Z. Desta Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A Antimicrob Agents Chemother 53 2009 541 551
54. J. Wagner, C. Suessmair, and H.W. Pfister Rhabdomyolysis caused by co-medication with simvastatin and clarithromycin J Neurol 256 2009 1182 1183
55. J.W. Grunden, and K.A. Fisher Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin Ann Pharmacother 31 1997 859 863 (Pubitemid 27332475)
56. G.W. Amsden, O. Kuye, and G.C. Wei A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers J Clin Pharmacol 42 2002 444 449 (Pubitemid 34259779)
57. P.H. Siedlik, S.C. Olson, and B.B. Yang Erythromycin coadministration increases plasma atorvastatin concentrations J Clin Pharmacol 39 1999 501 504 (Pubitemid 29356471)
58. D.H. Spach, J.E. Bauwens, and C.D. Clark Rhabdomyolysis associated with lovastatin and erythromycin use West J Med 154 1991 213 215
59. T. Kantola, K.T. Kivistö, and P.J. Neuvonen Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations Clin Pharmacol Ther 64 1998 177 182 (Pubitemid 28423853)
60. Ficha técnica de Alipza® (pitavastatina), texto actualizado Julio 2010. Lab Kowa Pharmaceutical Europe Co. Ltd.
61. C.A. Ciervo, and J. Shi Pharmacokinetics of telithromycin: application to dosing in the treatment of community-acquired respiratory tract infections Curr Med Res Opin 21 2005 1641 1650 (Pubitemid 41505030)
62. Ficha técnica de Ketek® (telitromicina), texto actualizado 31 Mayo 2010. Lab Aventis Pharma, S.A.
63. N.E. Azie, D.C. Brater, and P.A. Becker The interaction of diltiazem with lovastatin and pravastatin Clin Pharmacol Ther 64 1998 369 377 (Pubitemid 28473762)
64. J.J. Lewin 3rd, J.M. Nappi, and M.H. Taylor Rhabdomyolysis with concurrent atorvastatin and diltiazem Ann Pharmacother 36 2002 1546 1549
65. C.J. Fichtenbaum, J.G. Gerber, S.L. Rosenkranz, Y. Segal, J.A. Aberg, and T. Blascke Pharmacokinetic interactions between protease inhibitors and statins in seronegative volunteers: ACTG Study A5047 AIDS 16 2002 569 577 (Pubitemid 34218852)
66. Ficha técnica de Kaletra® (lopinavir/ritonavir), texto actualizado 7 Octubre 2008. Lab Abbott Laboratories Limited.
67. W. Yamreudeewong, M. DeBisschop, and L.G. Martin Potentially significant drug interactions of class III antiarrhythmic drugs Drug Saf 26 2003 421 438 (Pubitemid 36560714)
68. L. Becquemont, M. Neuvonen, C. Verstuyft, P. Jaillon, A. Letierce, and P.J. Neuvonen Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics Clin Pharmacol Ther 81 2007 679 684 (Pubitemid 46625102)
69. L. Roten, R.A. Schoenenberger, and S. Krähenbühl Rhabdomyolysis in association with simvastatin and amiodarone Ann Pharmacother 38 2004 978 981 (Pubitemid 38657737)
70. Ficha técnica de Trangorex® (amiodarona), texto actualizado Junio 2009. Lab SANOFI AVENTIS, S.A.
71. K.W. Kenyon, and J.M. Nappi Bosentan for the treatment of pulmonary arterial hypertension Ann Pharmacother 37 2003 1055 1062 (Pubitemid 36875240)
72. J. Dingemanse, D. Schaarschmidt, and P.L. van Giersbergen Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin Clin Pharmacokinet 42 2003 293 301 (Pubitemid 36308067)
73. M. Ucar, M. Neuvonen, and H. Luurila Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid Eur J Clin Pharmacol 59 2004 879 882 (Pubitemid 38333678)
74. M.B. Regazzi, I. Iacona, C. Campana, V. Raddato, C. Lesi, and G. Perani Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients Transplant Proc 25 1993 2732 2734 (Pubitemid 23239614)
75. M. Hedman, P.J. Neuvonen, and M. Neuvonen Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression Clin Pharmacol Ther 75 2004 101 109 (Pubitemid 38130122)
76. A. sberg Interactions between cyclosporin and lipidlowering drugs: implications for organ transplant recipients Drugs 63 2003 367 378
77. S.G. Simonson, A. Raza, P.D. Martin, P.D. Mitchell, J.A. Jarcho, and C.D. Brown Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine Clin Pharmacol Ther 76 2004 167 177 (Pubitemid 39013406)
78. T. Hasunuma, M. Nakamura, and T. Yachi The drug-drug interactions of pitavastatin (NK-104), a novel HMG-CoA reductase inhibitor and cyclosporine J Clin Ther Med 19 2003 381 389
79. W.P.D. Lemahieu, M. Hermann, A. Asberg, K. Verbeke, H. Holdaas, and Y. Vanrenterghem Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus Am J Transplant 5 2005 2236 2243 (Pubitemid 41648471)
80. M. Arnadottir, L.O. Eriksson, and H. Thysell Plasma concentration profiles of simvastatin 3-hydroxy- 3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin Nephron 65 1993 410 413 (Pubitemid 23321239)
81. N. Ichimaru, S. Takahara, Y. Kokado, J.D. Wang, M. Hatori, and H. Kameoka Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus Atherosclerosis 158 2001 417 423 (Pubitemid 32913652)
82. J.W. Park, R. Siekmeier, P. Lattke, M. Merz, C. Mix, and S. Schüler Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A J Cardiovasc Pharmacol Ther 6 2001 351 361 (Pubitemid 34141820)
83. H.M. Khandwala Lipid lowering inefficacy of high-dose statin therapy due to concurrent use of phenytoin South Med J 99 2006 1385 1387 (Pubitemid 46035558)
84. M.J. Murphy, and M.H. Dominiczak Efficacy of statin therapy: possible effect of phenytoin Postgrad Med J 75 1999 359 360 (Pubitemid 29237982)
85. Información técnica de Lovastatin; texto actualizado Enero 2008. Mylan Pharmaceuticals Inc. (Morgantown, WV -EE.UU-).
86. Información técnica de Simvastatin; texto actualizado Septiembre 2006. Ranbaxy Pharmaceuticals Inc.(Jacksonville, FL -EE.UU.-).
87. J.T. Backman, H. Luurila, and M. Neuvonen Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites Clin Pharmacol Ther 78 2005 154 167 (Pubitemid 41112284)
88. J.T. Backman, C. Kyrklund, and K.T. Kivistö Plasma concentrations of active simvastatin acid are increased by gemfibrozil Clin Pharmacol Ther 68 2000 122 129 (Pubitemid 30659167)
89. C. Kyrklund, J.T. Backman, and K.T. Kivistö Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate Clin Pharmacol Ther 69 2001 340 345 (Pubitemid 32477075)
90. J.D. Spence, C.E. Munoz, and L. Hendricks Pharmacokinetics of the combination of fluvastatin and gemfibrozil Am J Cardiol 76 1995 80 83
91. Ficha técnica de Trialmin; texto actualizado Mayo 2007. Lab Menarini SA.
92. R.Y. Gordon, D.J. Becker, and D.J. Rader Reduced efficacy of rosuvastatin by St. John's Wort Am J Med 122 2009 1 2
93. L. Andren, A. Andreasson, and R. Eggertsen Interaction between a commercially available St. John's wort product (Movina) and atorvastatin in patients with hypercholesterolemia Eur J Clin Pharmacol 63 2007 913 916 (Pubitemid 47387911)
94. R. Eggertsen, A. Andreasson, and L. Andren Effects of treatment with a commercially available St John's Wort product (Movina) on colesterol levels in patients with hypercholesterolemia treated with simvastatin Scand J Prim Health Care 25 2007 154 159 (Pubitemid 47398820)
95. K. Sugimoto, M. Ohmori, S. Tsuruoka, K. Nishiki, A. Kawaguchi, and K. Harada Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin Clin Pharmacol Ther 70 2001 518 524 (Pubitemid 34008408)
96. S.G. O'Brien, P. Meinhardt, E. Bond, J. Beck, B. Peng, and C. Dutreix Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia Br J Cancer 89 2003 1855 1859 (Pubitemid 37533259)
97. C.D. Scripture, and J.A. Pieper Clinical pharmacokinetics of fluvastatin Clin Pharmacokinet 40 2001 263 281 (Pubitemid 32458153)
98. C. Kyrklund, J.T. Backman, and K.T. Kivistö Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations Clin Pharmacol Ther 68 2000 592 597 (Pubitemid 32059984)
99. C. Kyrklund, J.T. Backman, M. Neuvonen, and P.J. Neuvonen Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects Br J Clin Pharmacol 57 2004 181 187 (Pubitemid 38223530)
100. S.R. Vavricka, J. Van Montfoort, and H.R. Ha Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver Hepatology 36 2002 164 172 (Pubitemid 34700774)
101. Y.Y. Lau, C.Y. Wu, and H. Okochi Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: hepatic enzyme-transporter interplay J Pharmacol Exp Ther 308 2004 1040 1045 (Pubitemid 38263980)
102. J.J. Lilja, K.T. Kivistö, and P.J. Neuvonen Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin Clin Pharmacol Ther 68 2000 384 390
103. T. Kantola, K.T. Kivistö, and P.J. Neuvonen Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid Clin Pharmacol Ther 63 1998 397 402 (Pubitemid 28214962)
104. J.J. Lilja, K.T. Kivistö, and P.J. Neuvonen Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin Clin Pharmacol Ther 66 1999 118 127 (Pubitemid 29398847)
105. H. Ando, S. Tsuruoka, H. Yanagihara, K. Sugimoto, M. Miyata, and Y. Yamazoe Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin Br J Clin Pharmacol 60 2005 494 497 (Pubitemid 41532449)
106. I. Fukazawa, N. Uchida, and E. Uchida Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese Br J Clin Pharmacol 57 2004 448 455 (Pubitemid 38519650)
107. J.D. Rogers, J. Zhao, L. Liu, R.D. Amin, K.D. Gagliano, and A.G. Porras Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors Clin Pharmacol Ther 66 1999 358 366 (Pubitemid 29494128)
108. J.P. Dreier, and M. Endres Statin-associated rhabdomyolysis triggered by grapefruit consumption Neurology 62 2004 670 (Pubitemid 38252822)
109. D.G. Bailey, and G.K. Dresser Interactions between grapefruit juice and cardiovascular drugs Am J Cardiovasc Drugs 4 2004 281 297 (Pubitemid 39429835)